Tiziana Life Sciences Regains Nasdaq Compliance, Secures Continued Listing

Tiziana Life Sciences ( (TLSA) ) has shared an update.

On March 4, 2025, Tiziana Life Sciences announced that it has regained compliance with the Nasdaq listing minimum bid price requirement, following a previous notification on January 29, 2025, regarding non-compliance. The company achieved the required minimum closing bid price of $1.00 for ten consecutive trading days by March 12, 2025, ensuring its continued listing on the Nasdaq Capital Market. This development is significant for Tiziana as it maintains its market presence and investor confidence, allowing it to continue its focus on developing innovative therapies for neuroinflammatory and neurodegenerative diseases.

More about Tiziana Life Sciences

Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies using transformational drug delivery technologies. The company specializes in immunomodulation therapies, with its lead candidate being intranasal foralumab, a fully human anti-CD3 monoclonal antibody. Tiziana’s innovative approach aims to improve efficacy, safety, and tolerability compared to traditional intravenous delivery methods.

YTD Price Performance: 117.65%

Average Trading Volume: 1,017,863

Technical Sentiment Consensus Rating: Sell

Current Market Cap: $158.2M

For a thorough assessment of TLSA stock, go to TipRanks’ Stock Analysis page.